Is Bax/Bcl-2 Ratio Considered as a Prognostic Marker with Age and Tumor Location in Colorectal Cancer?

Ehsan Khodapasand¹,2, Narges Jafarzadeh¹, Farid Farrokhi¹, Behnam Kamalideghhan¹ and Massoud Houshmand¹,2

¹Dept. of Research and Education, Razavi Hospital, Mashhad, Iran; ²National Institute for Genetic Engineering and Biotechnology, Tehran, Iran; ³Dept. of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received 12 August 2014; revised 18 August 2014; accepted 31 August 2014

ABSTRACT

Background: Bax and Bcl-2 are the major members of Bcl-2 family whose play a key role in tumor progression or inhibition of intrinsic apoptotic pathway triggered by mitochondrial dysfunction. Therefore, the balance between pro- and anti-apoptotic members of this family can determine the cellular fate. Methods: In this study, the relative level of mRNA expression of Bax and Bcl-2 genes was determined using RNA extraction, cDNA synthesis and RT-qPCR technique from 22 tumoral tissues and adjacent non-tumoral tissues from adenocarcinoma colorectal cancer. Results: The potential prognostic and predictive significance of Bax and Bcl-2 gene expression and Bax/Bcl-2 ratio were demonstrated in colorectal cancer. The significant correlation between qPCR data and different clinicopathologic parameters of colorectal carcinoma, including age, gender, tumor size, tumor stage, tumor location, and tumor differentiation was also examined. Interestingly, no significant correlation was seen between Bax and Bcl-2 expressions and clinicopathological parameters of colorectal cancer. However, Bax/Bcl-2 ratio was statistically correlated with age and tumor location. Patients with age above 50 showed decreased levels of Bax/Bcl-2 ratio. Moreover, the Bax/Bcl-2 ratio was significantly lower in tumors resected from colon compared to sigmoid colon, rectosigmoid and rectum tumors. Conclusion: This study indicates a significant correlation between age and tumor location with Bax/Bcl-2 expression ratio, suggesting predictive value as a potential molecular marker of colorectal cancer. Iran. Biomed. J. 19 (2): 69-75, 2015

Keywords: Colorectal cancer, Bax/Bcl-2 ratio, Bax expression, Bcl-2 expression

INTRODUCTION

Colorectal cancer is the third most common malignancy and the fourth common cause of cancer death across the world [1, 2]. A tendency for the annual increase in the incidence of the colorectal cancer has been observed [3]. Inhibition of apoptosis is a fundamental element in carcinogenesis of colorectal cancer and also other human malignancies [4, 5]. The ability of cancer cells to escape from apoptosis, which abolishes cells with harmful genetic defects, can transform these cells into fatal immortal colonies of cells, which are well known as tumors.

Bcl-2 family has been discovered to play a key role in promoting or inhibiting intrinsic apoptotic pathway triggered by mitochondrial dysfunction [6, 7]. Therefore, the balance between pro- and anti-apoptotic members of this family can determine the cellular fate. Bax and Bcl-2 are the major members of Bcl-2 family whose potential roles in tumor progression and prognosis of different human malignancies have been of interest in various studies during the last decade. Bax promotes cell death through permeabilization of mitochondrial outer membrane in response to different cellular stresses. In contrast, Bcl-2 prevents apoptosis by inhibiting the activity of Bax [7, 8]. It has been demonstrated that the absence of Bax expression in colorectal cancer cells can induce resistance to apoptosis triggered by different chemotherapeutic agents [9-11]. Conflicting results have been reported in the case of introducing Bax expression as an independent prognostic and predictive marker of colorectal cancer. Apparently, a significant correlation between longer survival and increased Bax expression in tumor cells has been observed in previous studies [12, 13]. However, in other studies, down-regulation and up-regulation of Bax and Bcl2 expressions were associated with better survival, respectively [13, 14].
These results became more confusing when therapeutic status of patients was considered [15]. It has been shown that in a surgery-alone group of patients, high Bax expression is associated with improved survival [16]. However, patients with lack or low Bax expression in their tumor cells, but not those with high expression, benefit from 5-FU-based adjuvant therapies. On the other hand, the role of Bcl-2 in development or progression of colorectal carcinoma and prognosis of the disease has not been fully elucidated [14].

The aim of the study was to determine the relative level of mRNA expression of Bax and Bcl-2 genes and Bax/Bcl-2 ratio in tumoral tissues and adjacent non-tumoral tissues, and to evaluate the correlation between Bax/Bcl-2 ratio and clinicopathological parameters of colorectal carcinoma.

**MATERIALS AND METHODS**

**Ethical statement and Sample collection.** Ethics approval and patients' informed consent, including consent to participate in the study and consent to publish were obtained for the present study in accordance to the Razavi Hospital and Medical Ethics Committee of Razavi Hospital (Approval No. RH.1018), Mashhad, Iran. A number of 22 patients with colorectal adenocarcinoma at various stage of progression were included in this study (Table 1). There were 15 males and 7 females with a median age of 50 years (range 16-84 years). Surgically removed tumoral tissues and adjacent non-tumoral tissues were collected and stored in RNAlater stabilization reagent (Qiagen, Germany) at 4°C, in which 14 and 8 tumors were removed from the rectum and colon, respectively.

**RNA extraction and cDNA synthesis.** Total RNA was extracted from tumoral tissues and adjacent non-tumoral tissues using the RNaseasy mini kit (Qiagen, Germany) according to the manufacturer’s instruction. The integrity of the extracted RNA was confirmed by electrophoresis on 1% agarose gel. The concentration and purity of RNA was identified using spectrophotometer (Amersham bioscience, UK). The cDNA was synthesized using Revert-aid first strand cDNA synthesis kit (Fermentas, Thermo Fisher Scientific, USA) using random hexamer primer according to the manufacturer’s instruction in 20-µl reaction mixture.

**Primer design.** Primers were designed using Primer3 software according to the published gene sequence in the Bax and Bcl-2 Gene Bank as reported (Table 2) in the literature and synthesized by TAG Company (Copenhagen, Denmark). Primer sequence homology and total gene specificity were confirmed with BLAST analysis (www.ncbi.nlm.nih.gov/blast). Each primer pair recognized at least one exon/intron junction to avoid amplification of genomic DNA.

**Table 1. Clinical characteristics of 22 patients with colorectal adenocarcinoma**

| Patient no. | Age | Sex | Site of primary | Tumor size (cm) | Grade | Stage |
|------------|-----|-----|----------------|-----------------|-------|-------|
| A00209     | 59  | F   | RECT           | 5.0             | I     | 2a    |
| A00360     | 34  | M   | RECT           | 3.0             | I     | 1     |
| A00422     | 52  | M   | RECT           | 6.0             | II    | 3b    |
| A00585     | 60  | F   | Rectosigmoid   | 2.5             | I     | 3b    |
| A00883     | 27  | M   | Rectosigmoid   | 4.5             | II    | 4     |
| A00933     | 53  | M   | Rectosigmoid   | 5.0             | I     | 4     |
| A00948     | 48  | M   | RECT           | 4.0             | II    | 2a    |
| A00997     | 55  | F   | RECT           | 5.0             | I     | 2a    |
| A01118     | 62  | M   | Colon, NOS     | 4.0             | I     | 2a    |
| A01180     | 19  | M   | RECT           | 5.0             | III   | 3b    |
| A01187     | 16  | M   | Sigmoid Colon  | 7.0             | III   | 3b    |
| A01237     | 48  | M   | Colon, NOS     | 6.0             | III   | 3c    |
| A01293     | 64  | M   | Rectosigmoid   | 4.0             | I     | 3c    |
| A01294     | 67  | M   | Rectum         | 2.5             | II    | 3c    |
| A01297     | 56  | F   | Sigmoid Colon  | 8.0             | I     | 2a    |
| A01303     | 63  | M   | Rectum         | 6.0             | III   | 3c    |
| A01357     | 84  | F   | Colon, NOS     | 10.0            | II    | 2a    |
| A01361     | 80  | F   | Sigmoid Colon  | 6.5             | I     | 3b    |
| A01384     | 50  | F   | Rectum         | 3.5             | I     | 2a    |
| A01387     | 46  | M   | Rectosigmoid   | 4.5             | II    | 2a    |
| A01447     | 66  | M   | Colon, NOS     | 3.0             | I     | 1     |
| A01448     | 55  | M   | Sigmoid Colon  | 3.6             | I     | 3     |

F, female; M, male; NOS, not otherwise specified; RECT, rectosigmoid

http://IBJ.pasteur.ac.ir
**Quantitative RT-PCR.** Relative expression of Bax and Bcl-2 genes was performed using 2 µl synthesized cDNA (1,600 ng/µl) as the template in 12.5 µl SYBR Green PCR Master Mix and 2 µl each primer using Rotor-Gene 6000 real-time rotary analyzer (Corbett Life Science, USA). Then, the following conditions were selected: 95ºC-10 min, 45 cycles: 95ºC-30 s, 59ºC-30 s, and 72ºC-45 s. β-actin was used as endogenous control gene, and all experiments were performed in triplicate for each data point. The specificity of qPCR reaction was confirmed by melt curve analysis and electrophoresis of PCR products on 1.5% agarose gel. Standard curves for each of β-actin, Bax, and Bcl-2 genes were generated by amplifying 5× serial dilutions of cDNA created from RNA isolated from normal tissue. Two standard curve methods (Rotor-Gene 6000 series software, v1.7) were used for relative quantitation of Bax and Bcl-2 mRNA expression (Copies/µl), and the triplicate samples were assessed for variability using geometric standard deviations. The geometric mean of the triplicate run for each gene of interest was normalized with the geometric mean of β-actin.

**Statistical analysis.** All statistical analyses were performed using SPSS v.16 (IBM, Chicago, IL, USA). Correlations between relative level of expression of Bax and Bcl-2 genes and age, tumor stage, and tumor size of the patients were analyzed using Pearson's correlation coefficient. t-test was also used to analyze the significance of patient’s gender. Furthermore, correlation of expression rates with remaining parameters, including tumor location and differentiation was performed using one-way ANOVA, followed by a Tukey's post hoc test. Differences between Bax/Bcl-2 ratio in normal and tumoral tissue were also analyzed using paired t-test. P value < 0.05 was considered statistically significant.

**RESULTS AND DISCUSSION**

Dysregulation of the mitochondrial pathway of apoptosis is one of the most important events during carcinogenesis. Bcl-2 protein family, including anti-apoptotic (e.g. Bcl-2, Bcl-xl, and Mcl-1) and pro-apoptotic (e.g. Bax, Bak) members play a central role in regulation of this pathway [17]. Relative level of mRNA expression of Bax and Bcl-2 genes and Bax/Bcl-2 ratio was evaluated in tumoral and adjacent non-tumoral tissues of colorectal cancer patients. Regarding statistical analysis, no significant correlation was observed between relative level expression of Bax and Bcl-2 with different clinicopathological parameters, including age, gender, tumor size, tumor location, tumor stage, and tumor differentiation (Table 3). According to our results, Bax and Bcl-2 expression was not significantly correlated with patient’s gender and age less than 50, size, stage (I-IV), differentiation status, and location of primary tumor which could be colon, sigmoid colon, rectosigmoid, and rectum (P > 0.05). However, Bax/Bcl-2 ratio was significantly (P < 0.05) correlated with patient’s age above 50 (Fig. 1), and site of primary tumor in colon (Fig. 2), in comparison to other sites, including sigmoid colon, rectosigmoid, and rectum (P > 0.05).

**Table 2. Primer sequences used for QRT-PCR**

| Primer  | Sequences                                      | T°c |
|---------|------------------------------------------------|-----|
| Bax     | Forward: 5'-CCTGTGCACCAAGGTGCCGA-3'   Reverse: 5'-CCACCTTGCTGATCCAGGCC-3' | 59ºC |
| Bcl-2   | Forward: 5'-TTTGGCCCTTTGAGGTCGTCG-3'   Reverse: 5'-GGTGCGGCTTCAGGTACT-3'   | 59ºC |
| β-actin | Forward: 5'-GGCGGCACCACCATGTACC-3'    Reverse: 5'-AGGGGCCGTGCTACT-3'   | 59ºC |

![Fig. 1. Correlation of Bax/Bcl-2 ratio with patient’s age. The ratio decreased in patients with age above 50, indicating an inverse correlation between Bax/Bcl-2 ratio and age.](http://ibj.pasteur.ac.ir)
Table 3. Correlation between the expression of Bax and Bcl-2 with clinicopathological features of patients with colorectal cancer

| Characteristics                  | No ( %) | Relative Bax expression (tumor/normal) (no. %) | Relative Bcl-2 expression (tumor/normal) (no %) | Bax/Bcl-2 ratio (No %) |
|----------------------------------|---------|-----------------------------------------------|------------------------------------------------|------------------------|
|                                  |         | >1    | <1   | P value | >1    | <1   | P value | >1   | <1   | P value |
| Gender                           |         |       |      |         |       |      |         |       |      |         |
| Male                             | 15 (68.2) | 10 (66.7) | 5 (33.3) | 0.581 | 11 (73.3) | 4 (26.7) | 0.883 | 7 (46.7) | 8 (53.3) | 0.917 |
| Female                           | 7 (31.8) | 5 (71.4) | 2 (28.6) |       | 6 (85.7) | 1 (14.3) |       | 5 (71.4) | 2 (28.6) |       |
| Age                              |         |       |      |         |       |      |         |       |      |         |
| <50                              | 7 (31.8) | 5 (71.4) | 2 (28.6) | 0.148 | 6 (85.7) | 1 (14.3) | 0.199 | 4 (57.1) | 3 (42.9) | 0.049* |
| ≥50                              | 15 (68.2) | 10 (66.7) | 5 (33.3) |       | 10 (66.7) | 5 (33.3) |       | 8 (53.3) | 7 (46.7) |       |
| Site of primary tumor            |         |       |      |         |       |      |         |       |      |         |
| Colon                            | 8 (36.4) | 3 (37.5) | 5 (62.5) | 0.126 | 6 (75.0) | 2 (25.0) | 0.513 | 4 (50.0) | 4 (50.0) | 0.020* |
| Rectum                           | 14 (63.6) | 12 (85.7) | 2 (14.3) |       | 10 (71.4) | 4 (28.6) |       | 9 (64.3) | 5 (35.7) |       |
| Tumor differentiation            |         |       |      |         |       |      |         |       |      |         |
| Well                             | 12 (54.5) | 9 (75.0) | 3 (25.0) | 0.852 | 8 (66.7) | 4 (33.3) | 0.663 | 9 (75.0) | 3 (25.0) | 0.428 |
| Moderate                         | 6 (27.3) | 4 (66.7) | 2 (33.3) |       | 5 (83.3) | 1 (16.7) |       | 3 (50.0) | 3 (50.0) |       |
| Poor                             | 4 (18.2) | 2 (50.0) | 2 (50.0) |       | 3 (75.0) | 1 (25.0) |       | 1 (25.0) | 3 (75.0) |       |
| Tumor size                       |         |       |      |         |       |      |         |       |      |         |
| <4.8                             | 11 (50.0) | 10 (90.9) | 1 (9.1) | 0.778 | 9 (81.8) | 2 (18.2) | 0.424 | 7 (63.6) | 4 (36.7) | 0.187 |
| ≥4.8                             | 11 (50.0) | 7 (63.6) | 4 (36.7) |       | 7 (63.6) | 4 (36.7) |       | 6 (54.5) | 5 (45.5) |       |
| Tumor stage                      |         |       |      |         |       |      |         |       |      |         |
| I                                | 2 (9.1) | 1 (50.0) | 1 (50.0) |       | 1 (50.0) | 1 (50.0) |       | 1 (50.0) | 1 (50.0) |       |
| II                               | 8 (36.4) | 5 (62.5) | 3 (37.5) | 0.794 | 6 (75.0) | 2 (25.0) | 0.906 | 6 (75.0) | 2 (25.0) | 0.818 |
| III                              | 10 (45.4) | 7 (70.0) | 3 (30.0) |       | 7 (70.0) | 3 (30.0) |       | 3 (30.0) | 7 (70.0) |       |
| IV                               | 2 (9.1) | 2 (100.0) | 0 (0) |       | 1 (50.0) | 1 (50.0) |       | 2 (100.0) | 0 (0.0) |       |

* Statistically significant P < 0.05.
As indicated in previous studies, expression of Bax and Bcl-2 proteins may be helpful in predicting clinical outcome [14, 18], patient’s survival [12], and even response to chemotherapeutic agents in colorectal carcinoma [9, 15]. We analyzed the relative expression of these two proteins at mRNA level in a heterogeneous group of patients with colorectal carcinoma using qPCR technology.

There are increasing evidences trying to prove the prognostic and predictive role of apoptosis-related markers such as Bax and Bcl-2. Sturm et al. [12] reported that in patients with hepatic metastasis of colorectal cancer, high Bax expression was correlated with longer survival, especially in patients with wild-type p53. In accordance with previous studies, Katkooi et al. [15] reported that in the surgery-alone group, high Bax expression was associated with better survival. They showed that in a group of patients who underwent 5-FU-based adjuvant chemotherapy, low Bax expression was associated with improved survival, suggesting that there are apparently distinct mechanisms of Bax involvement in the manifestation of apoptosis triggered by chemotherapeutic agents. Interestingly, various investigations have shown that in colorectal cancer cells lacking Bax, apoptosis can be partially or completely abolished in response to chemotherapeutic agents such as 5-FU and sulindac [9-11]. Jansson and Sun [18] have demonstrated that Bax expression is decreased from primary to metastatic and also from well/moderately to poorly differentiated
tumors. Furthermore, in this study, the cases with decreased Bax expression from primary tumors to the corresponding metastases showed a more infiltrative growth pattern, more distant metastases, and a weak trend toward poor prognosis, indicating the involvement of Bax expression in tumor differentiation and metastatic progression.

Although lots of studies have been done on the prognostic significance of counteracting twin of Bcl-2 and Bax, most of them failed to find a significant relationship between Bcl-2 expression levels and clinicopathological parameters of colorectal cancer. A possible explanation for these results can be the presence of other members of Bcl-2 family which can act independently from Bcl-2 [3, 11, 19, 20]. Bax/Bcl-2 ratio can act as a rheostat which determines cell susceptibility to apoptosis [21]. Lower levels of this ratio may lead to resistance of human cancer cells to apoptosis. Thus, Bax/Bcl-2 ratio can affect tumor progression and aggressiveness. Our results are in line with a previous study which suggested that low levels of Bax/Bcl-2 ratio may result in poor prognosis and more infiltrative growth pattern in older patients [22].

On the other hand, it has been demonstrated that location of primary tumor has a critical role in determining tumor characteristics and prognosis of the cancer [23, 24]. Our findings remarked the importance of location of primary tumor and indicated that tumors resected from colon have different gene expression profile especially in the case of Bax and Bcl-2, which can affect tumor characteristics. These tumors seem to be more aggressive compared to tumors located in the other sites.

In accordance with a previous study [25], relative level of expression of Bax and Bcl-2 failed to reach statistical significance. Paradoxical behavior of tumor cells in expressing different oncogenes and tumor suppressor genes, which has been reported in various studies [18, 26], and also dysregulation of many intracellular signaling pathways, which make them difficult to understand, might be accounted for this finding. However, there is a stronger possibility that different chemotherapeutic agents may affect the expression level and clinical roles of molecules, which involve in apoptosis, especially Bax and Bcl-2 [15]. In this study, a group of patients independent of their therapeutic status was analyzed. Therefore, their possible chemotherapy either radiotherapy regimens may have altered the expression levels of Bax and Bcl-2 proteins. Prognostic and predictive role of Bcl-xl gene expression in colorectal cancer has also been reported by some researchers [27, 28]. Moreover, expression analysis of BH3-only members, a group of small molecules with pro-apoptotic activity, may be helpful in elucidating alterations in Bax and Bcl-2 expression level in human colorectal carcinoma [8].

In conclusion, Bax and Bcl-2 expression was most predictive of outcome when combined as Bax/Bcl-2 expression ratio in colorectal tumors compared to expression levels of Bax and/or Bcl-2 genes alone. Moreover, further analyses on larger homogeneous cohorts of patients with similar therapeutic status and also tumor characteristics such as tumor stage and differentiation may be very useful from different aspects, including prognosis of the disease, predicting patient’s survival, tumor relapse, and also response to chemotherapeutic agents.

ACKNOWLEDGMENTS

We are thankful to the Research and Education Department of Mashhad Razavi Hospital (Mashhad, Iran) for giving the grant for this project.

REFERENCES

1. Haggar FA, Boushey RP: Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov; 22(4):191-7.
2. Ward S, Hepburn E, Li K, Curwishley S, Hejmdr I, Ismaeel T, Bicknell R, Rot A, Adams D: Selective recruitment and retention of regulatory T cells in human colorectal cancer. The Lancet. 2013; 381:S113.
3. Sun N, Meng Q, Tian A: Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg. 2010 Sep; 200(3):341-5.
4. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011 Mar 4; 144(5):646-74.
5. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000 Jan 7; 100(1):57-70.
6. Yip KW, Reed JC: Bcl-2 family proteins and cancer. Oncogene. 2008 Oct 27; 27(50):6398-406.
7. Mohan S, Abdelwahab SI, Kamalidehghan B, Syam S, May KS, Harmal NSM, Shafiiyaz N, Hadi AHA, Hashim NM, Rahmani M: Involvement of NF-xB and Bcl2/Bax signaling pathways in the apoptosis of MCF7 cells induced by a xanthone compound Pyranocycloartobiloxanthone A. Phytomedicine. 2012; 19(11):1007-15.
8. Hector S, Prehn JH: Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta. 2009 Apr; 1795(2):117-29.
9. Zhang L, Yu J, Park BH, Kiznter KW, Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3; 290(5493):989-92.
10. Rashmi R, Kumar S, Karunaganaran D: Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis. 2005 Apr; 26(4):713-23.
11. Nehls O, Okech T, Hsieh CJ, Enzinger T, Sarbia M, Borchard F, Gruenagel HH, Gaco V, Hass HG, Arkenau HT et al: Studies on p53, BAX and Bcl-2 protein...
expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX. Br J Cancer. 2007 May 7; 96(9):1409-18.

12. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT: Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999 May; 17(5):1364-74.

13. Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefer GJ, van de Velde CJ, Kuppen PJ: The prognostic Value of the Apoptosis pathway in colorectal Cancer: A Review of the Literature on Biomarkers Identified by Immunohistochemistry. Biomarkers in cancer. 2013; 5:13.

14. Tsamandas AC, Kardamakis D, Petsas T, Zolota V, Vassiliou V, Matatosis T, Kalofonos H, Vigano CE, Scopa CD: Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome. In Vivo. 2007 Jan-Feb; 21(1):113-8.

15. Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messina L, Posey J, 3rd, Bumpers HL, Meleth S, Grizzle WE et al: Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010 Dec; 1(2):76-89.

16. Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messina L, et al. Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol. 2010 Dec; 1(2):76-89.

17. Packham G: Mutation of BCL-2 Family Proteins in Cancer. Apoptosis. 1998 Mar; 3(2):75-82.

18. Jansson A, Sun XF: Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol. 2002 Feb 1; 20(3):811-6.

19. Zhao DP, Ding XW, Peng JP, Zheng YX, Zhang SZ: Prognostic significance of bcl-2 and p53 expression in colorectal carcinoma. J Zhejiang Univ Sci B. 2005 Dec; 6(12):1163-9.

20. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamplum H, Collan Y, Pyrhonen S: Apoptotic index and bcl-2 expression as prognostic factors in colorectal carcinoma. Oncology. 2003; 64(4):435-42.

21. Raisova M, Hassan AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfano CE, Geilen CC: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol. 2001 Aug; 117(2):333-40.

22. Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Bermejo JL: Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010; 10:688.

23. Bufill JA: Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location. Annals of Internal Medicine. 1990; 113(10):779-88.

24. Wray CM, Zigras A, Hinojosa MW, Le H, Stamos MJ, Zell JA: Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009 Aug; 52(8):1359-66.

25. Paradiso A, Simone G, Lena MD, Leone B, Vallejo C, Lacava J, Delapasqua S, Daidone MG, Costa A: Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. Br J Cancer. 2001 Mar 2; 84(5):651-8.

26. Paul-Samojedny M, Kokocinska D, Samojedny A, Mazurek U, Partyna R, Lorenz Z, Wilczok T: Expression of cell survival/death genes: Bcl-2 and Bax at the rate of colon cancer prognosis. Biochim Biophys Acta. 2005 Jun 30; 1741(1-2):25-9.

27. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, Wei D: Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 2011 Dec; 113(8):810-4.

28. De Angelis PM, Stokke T, Thorstensen L, Lothe RA, Clausen OP: Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. Mol Pathol. 1998 Oct; 51(5):254-61.

http://IBJ.pasteur.ac.ir